Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Jan Bewersdorf

Jan Bewersdorf

MD
Yale Cancer Center

Academic History

Jan Philipp Bewersdorf, MD, is an Assistant Professor of Medicine (Hematology) at Yale University. Dr Bewersdorf earned his medical degree in Germany, and completed his Internal Medicine training at Yale (New Haven Hospital). After his residency, Dr Bewersdorf pursued his fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center, New York, NY, before joining the faculty at Yale in July 2024.

Speaking on the pathophysiology of AML and MDS

Dr Bewersdorf is an up-and-coming young researcher, focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He seeks to improve understanding of the underlying pathophysiology of these diseases, particularly the role of the immune system. Dr Bewersdorf also undertakes research into health economics and clinical epidemiology in order to improve patient care.

A Phase Ib study of PRT503, a PRMT5 inhibitor, in R/R splicing factor-mutated myeloid malignancies 3:16
A Phase Ib study of PRT503, a PRMT5 inhibitor, in R/R splicing factor-mutated myeloid malignancies
Jan Bewersdorf • 7 Dec 2024
A subgroup analysis of the FUSION trial: azacitidine plus durvalumab in SF-mutated AML or MDS 2:42
A subgroup analysis of the FUSION trial: azacitidine plus durvalumab in SF-mutated AML or MDS
Jan Bewersdorf • 7 Dec 2024
A cost-effective analysis of alloSCT versus consolidation chemotherapy in intermediate-risk AML 3:28
A cost-effective analysis of alloSCT versus consolidation chemotherapy in intermediate-risk AML
Jan Bewersdorf • 7 Dec 2024
Validation of IWG 2023 criteria for response to treatment with HMA in HR-MDS 2:48
Validation of IWG 2023 criteria for response to treatment with HMA in HR-MDS
Jan Bewersdorf • 10 Dec 2023
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine 2:00
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Jan Bewersdorf • 10 Dec 2023
E7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies 1:43
E7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies
Jan Bewersdorf • 10 Dec 2023
Intensive induction chemotherapy vs HMA/Ven in NPM1-mutant AML: a retrospective study 2:36
Intensive induction chemotherapy vs HMA/Ven in NPM1-mutant AML: a retrospective study
Jan Bewersdorf • 10 Dec 2023
The genetic landscape of MDS: how this is improving & impacting the development of therapies 3:36
The genetic landscape of MDS: how this is improving & impacting the development of therapies
Jan Bewersdorf • 6 Oct 2023
The efficacy of FLT3 and IDH1/2 inhibitors in patients with AML previously treated with venetoclax 3:57
The efficacy of FLT3 and IDH1/2 inhibitors in patients with AML previously treated with venetoclax
Jan Bewersdorf • 6 Oct 2023
Venetoclax-based salvage therapy in patients with R/R AML previously treated with targeted agents 2:16
Venetoclax-based salvage therapy in patients with R/R AML previously treated with targeted agents
Jan Bewersdorf • 6 Oct 2023
How can we improve the cost-effectiveness of AML treatment? 3:17
How can we improve the cost-effectiveness of AML treatment?
Jan Bewersdorf • 6 Oct 2023
Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosis 2:51
Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosis
Jan Bewersdorf • 18 Apr 2023
Novel approaches being explored for patients with accelerated and blast-phase MPNs 1:35
Novel approaches being explored for patients with accelerated and blast-phase MPNs
Jan Bewersdorf • 18 Apr 2023
The efficacy of venetoclax-based salvage therapy in patients with previously treated R/R AML 1:59
The efficacy of venetoclax-based salvage therapy in patients with previously treated R/R AML
Jan Bewersdorf • 18 Apr 2023
Impact of allelic state on OS in TP53-mutant AML and HR-MDS 2:26
Impact of allelic state on OS in TP53-mutant AML and HR-MDS
Jan Bewersdorf • 11 Dec 2022
Phase II study of E7820 in patients with splicing factor-mutant myeloid malignancies 2:36
Phase II study of E7820 in patients with splicing factor-mutant myeloid malignancies
Jan Bewersdorf • 11 Dec 2022
The content of VJHemOnc is intended for healthcare professionals